Insights from ESC: Treat Earlier, Implement Better, and Question What We Thought We Knew
Season 2 Episode 93 · Aug 31, 07:30 PM
Share
Subscribe
Craig Beavers unpacks Days 2–3 of ESC 2026—from STAREE and REACT to TIME-HF—and why getting proven therapies to patients now matters most.
Trials Discussed:
STAREE (NCT02099123)
REACT (NCT06692127)
AMUNDSEN (NCT04951856)
ENRICH-AF (NCT03950076)
LIBREXIA-ACS (NCT05754957)
PREMIUM (NCT05709626)
SWITCH SWEDEHEART (NCT05183178)
EMAIL-HF (NCT05890131)
ADHERE-ASCVD (NCT07522645)
TIME-HF (CTRI/2021/11/037797)
H-HeFT & Met-HeFT (DANHEART, NCT03514108)
ACASA-TAVI (NCT05035277)
STAREE (NCT02099123)
REACT (NCT06692127)
AMUNDSEN (NCT04951856)
ENRICH-AF (NCT03950076)
LIBREXIA-ACS (NCT05754957)
PREMIUM (NCT05709626)
SWITCH SWEDEHEART (NCT05183178)
EMAIL-HF (NCT05890131)
ADHERE-ASCVD (NCT07522645)
TIME-HF (CTRI/2021/11/037797)
H-HeFT & Met-HeFT (DANHEART, NCT03514108)
ACASA-TAVI (NCT05035277)